Clinical Trial Update: A 24-week Study Evaluating the Effectiveness and Safety of Lucentis® 0.2mg in Retinopathy of Prematurity Participants in China

View source ↗

Summary

A 24-week clinical trial in China evaluating the effectiveness and safety of Lucentis (ranibizumab) 0.2 mg for retinopathy of prematurity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Retinopathy of Prematurity | Status: COMPLETED